Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

Core Insights - Absci Corporation has announced a strategic collaboration with AMD, which includes a $20 million equity investment to enhance AI drug discovery capabilities [1][2][3] - The partnership aims to optimize AI solutions for complex biological modeling, improving performance, reducing costs, and accelerating innovation cycles in drug development [2][3] Company Overview - Absci is a data-first generative AI drug creation company that integrates AI with scalable wet lab technologies to expedite the development of biologics [4] - The company’s Integrated Drug Creation platform allows for rapid screening of billions of cells weekly, enabling a transition from AI-designed candidates to wet lab-validated candidates in as little as six weeks [4] AMD's Role - AMD will provide its Instinct accelerators and ROCm software to support Absci's AI drug discovery workloads, particularly in advanced antibody design [1][2] - AMD's high-performance computing solutions are tailored for demanding AI workloads, making them a suitable partner for Absci's innovative drug discovery efforts [3][5] Strategic Importance - The collaboration is positioned to enhance Absci's ability to develop next-generation antibody therapeutics and transform the biologic drug development process [3][5] - Absci's CEO highlighted the partnership as a unique advantage in pushing the boundaries of drug discovery through efficient and innovative AI solutions [3]